Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Other Small Molecule Therapeutic Agents

BI-33, a novel and potent pan-Bcl-2 inhibitor, induces apoptosis in cancer cells and shows combinational effect with chemo drugs

Feng Jiang, Jianting Long, Sanjeev Shangary, Su Qiu, Meilan Liu, Guozhi Tang, ke Ding, Zaneta Nikolovska-Coleska, Dajun Yang and Shaomeng Wang
Feng Jiang
University of Michigan, Ann Arbor, MI, Ascenta Therapeutics, Inc., San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianting Long
University of Michigan, Ann Arbor, MI, Ascenta Therapeutics, Inc., San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjeev Shangary
University of Michigan, Ann Arbor, MI, Ascenta Therapeutics, Inc., San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Su Qiu
University of Michigan, Ann Arbor, MI, Ascenta Therapeutics, Inc., San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meilan Liu
University of Michigan, Ann Arbor, MI, Ascenta Therapeutics, Inc., San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guozhi Tang
University of Michigan, Ann Arbor, MI, Ascenta Therapeutics, Inc., San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ke Ding
University of Michigan, Ann Arbor, MI, Ascenta Therapeutics, Inc., San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zaneta Nikolovska-Coleska
University of Michigan, Ann Arbor, MI, Ascenta Therapeutics, Inc., San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dajun Yang
University of Michigan, Ann Arbor, MI, Ascenta Therapeutics, Inc., San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaomeng Wang
University of Michigan, Ann Arbor, MI, Ascenta Therapeutics, Inc., San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published November 2007
  • Article
  • Info & Metrics
Loading
AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics-- Oct 22-26, 2007; San Francisco, CA

Abstract

C229

Introduction: BI-33 is a novel flavonoid compound which mimics the Bim BH3 peptide. Our study is to determine the biological effect of BI-33 and its therapeutic potential used as a single agent or in combinational treatment with chemo drugs.
Experimental Procesures: BI-33 binds to Bcl-2, Bcl-xL and Mcl-1 with Ki value at 17nM, 1.2uM and 18nM, respectively, as shown in fluorescence-polarization-based binding assay. BI-33 inhibits cell growth in 2LMP breast cancer cell line and PC3 prostate cancer cell line as shown by 4 days WST assay, with IC50 at 50nM and 40nM, respectively. BI-33 used at 1uM for 4 days induces ~50% of cell death in these two cell lines as demonstrated by trypan blue assay and confirmed by AnnexinV-PI apoptotic assay. BI-112, served as compound control which has low binding affinity to Bcl-2, Bcl-xL and Mcl-1, does not induce cell death even at 10uM. To determine if mitochondrial apoptotic pathway is activated by BI-33, cytochrome C release and caspase3 activation is investigated. BI-33 at 10uM for 2 days induces cytochrome C release in cytosolic fraction and PARP cleavage in nuclear fraction from 2LMP cells. Caspase3 activity was increased 6 fold by BI-33 in 2LMP cells. To further determine if BI-33 targets Bcl-2 or Bcl-xL for cell killing, stable clones of Bcl-2 or Bcl-xL in MDA-MB-435 cells were established and confirmed the increased resistance to VP16. BI-33 counters overexpression of Bcl-2 or Bcl-xL as shown by efficient killing of these stable clones. To investigate if BI-33 synergizes with chemo drugs to induce cell death, Paclitaxel is tested in 2LMP cells and IC50 of Paclitaxel is decreased 10 fold by co-treatment with BI-33. We further tested Jurkat cells with overexpression of Bcl-2 or Bcl-xL, which show increased resistance to VP-16. BI-33 can also sensitize these stable clones to VP-16 treatment.
Conclusion: Taken together, our study shows that BI-33, as a pan-Bcl-2 inhibitor, induces cancer cell death through activation of mitochondrial apoptotic pathway, and has potential to be used as single agent or in combinational treatment with chemotherapy, to kill cancer cells which have high level of Bcl-2, Bcl-xL and Mcl-1.

Footnotes

  • AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics-- Oct 22-26, 2007; San Francisco, CA

  • American Association for Cancer Research
Previous
Back to top
Molecular Cancer Therapeutics: 6 (11 Supplement)
November 2007
Volume 6, Issue 11 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
BI-33, a novel and potent pan-Bcl-2 inhibitor, induces apoptosis in cancer cells and shows combinational effect with chemo drugs
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
BI-33, a novel and potent pan-Bcl-2 inhibitor, induces apoptosis in cancer cells and shows combinational effect with chemo drugs
Feng Jiang, Jianting Long, Sanjeev Shangary, Su Qiu, Meilan Liu, Guozhi Tang, ke Ding, Zaneta Nikolovska-Coleska, Dajun Yang and Shaomeng Wang
Mol Cancer Ther November 1 2007 (6) (11 Supplement) C229;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
BI-33, a novel and potent pan-Bcl-2 inhibitor, induces apoptosis in cancer cells and shows combinational effect with chemo drugs
Feng Jiang, Jianting Long, Sanjeev Shangary, Su Qiu, Meilan Liu, Guozhi Tang, ke Ding, Zaneta Nikolovska-Coleska, Dajun Yang and Shaomeng Wang
Mol Cancer Ther November 1 2007 (6) (11 Supplement) C229;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Other Small Molecule Therapeutic Agents

  • Preclinical potential of TRAIL-death receptor agonist for the treatment of human prostate cancer
  • Identification of inhibitors of Rb-Raf-1 binding. A new target for anticancer drug design.
Show more Other Small Molecule Therapeutic Agents

Other Small Molecule Therapeutic Agents: Poster Presentations

  • Preclinical potential of TRAIL-death receptor agonist for the treatment of human prostate cancer
  • Identification of inhibitors of Rb-Raf-1 binding. A new target for anticancer drug design.
  • Evaluation of topoisomerase I inhibitors, antitubulin inhibitors, and antimetabolites in bone marrow CFU-GM assays
Show more Other Small Molecule Therapeutic Agents: Poster Presentations
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement